Skip to content

US · NAMSW · BIOTECHNOLOGY

NewAmsterdam Pharma Company N.V. (NAMSW) intrinsic value and stock valuation

$18.45as of 2026-09-18 · Mkt cap 2.44B

Data updated · price as of 2026-09-18

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

NewAmsterdam Pharma Company N.V. DCF and intrinsic value

InvestorsCraft values NAMSW with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from NAMSW’s statements →

NewAmsterdam Pharma Company N.V. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Naarden, NH, NL newamsterdampharma.com

How the business is doing

Fiscal 2025–2020, USD

Revenue
$0.00
20252020
Net income
-$-7.02T
20252020
Free cash flow
-$-7.36T
20252020
Total equity
$127.5T-28.5% 5y CAGRd
20252020

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2025–2020, USD
FYFYFYFYFY
Revenue$22.5T$45.6T$14.1T$102.7T$0.00
Operating income-$-225.68T-$-176.29T-$-182.97T-$-3.56T-$-34.98T
Net income-$-203.82T-$-241.6T-$-176.94T-$-22.63T-$-41.79T
EPSd-$-1.78M-$-2.56M-$-2.15M-$-1.19M-$-2.35M
Operating cash flow-$-147.78T-$-158.56T-$-141.22T$10.7T-$-29.51T
Capital expenditure-$-246B-$-672B-$-24B-$-221B-$-24B
Free cash flow-$-148.03T-$-159.24T-$-141.24T$10.4T-$-29.54T
Total assets$769.3T$864.6T$347.1T$478.5T$68T
Total debt$202B$448B$60B$126B$186.5B
Net debt-$-489.8T-$-771.3T-$-340.39T-$-467.6T-$-60.19T
Total equity$683.4T$757.5T$288.4T$430.1T$56.6T
Cash and short-term investments$636.2T$834.2T$340.5T$467.7T$60.4T
Income statement
FYFYFYFYFY
Revenue$22.5T$45.6T$14.1T$102.7T$0.00
Cost of revenue$59B$0.00$0.00$0.00$0.00
Gross profit$22.4T$45.6T$14.1T$102.7T$0.00
Research and development expenses$141.8T$151.4T$159.4T$86.7T$29T
Selling, general and administrative expenses$106.3T$70.4T$37.6T$19.5T$5.68T
Other expenses$0.00$0.00$0.00$0.00$326B
Operating expenses$248.1T$221.9T$197.1T$106.3T$35T
Cost and expenses$248.2T$221.9T$197.1T$106.3T$35T
Interest income$27.6T$16.9T$10.2T$0.00$0.00
Interest expense$0.00$0.00$6.8T$287B$411B
Depreciation and amortization$220B$113B$49B$9B$5B
Ebitda-$-242.33T-$-241.49T-$-176.86T-$-22.34T-$-41.37T
Operating income-$-225.68T-$-176.29T-$-182.97T-$-3.56T-$-34.98T
Total other income/expenses, net$21.9T-$-65.31T$6.06T-$-19.08T-$-6.81T
Income before tax-$-203.82T-$-241.6T-$-176.91T-$-22.63T-$-41.79T
Income tax expense$0.00-$-1B$27B$0.00$0.00
Net income-$-203.82T-$-241.6T-$-176.94T-$-22.63T-$-41.79T
Weighted average shares outstanding$114.4T$94.4T$82.2T$19T$17.8T
Weighted average diluted shares outstanding$114.4T$94.4T$82.2T$19T$17.8T
Balance sheet
FYFYFYFYFY
Cash and short-term investments$636.2T$834.2T$340.5T$467.7T$60.4T
Net receivables$23.2T$21.3T$1.88T$0.00$5.51T
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$675.7T$863.4T$346.8T$478T$67T
Property, plant and equipment, net$568B$673B$101B$154B$216.1B
Goodwill and intangible assets$407B$534B$170B$208B$0.00
Long-term investments$0.00$0.00$0.00$0.00$138T
Total non-current assets$93.6T$1.21T$306B$518B$1.03T
Total assets$769.3T$864.6T$347.1T$478.5T$68T
Accounts payable$8.97T$4.74T$16.9T$11.9T$7.07T
Short-term debt$136B$246B$60B$66B$60.3B
Deferred revenue$3.99T$6.01T$8.94T$0.00$0.00
Total current liabilities$85.8T$106.9T$49.9T$36.1T$11.2T
Long-term debt$66B$202B$0.00$60B$126.2B
Deferred revenue, non-current$0.00$0.00$1.02T$0.00$0.00
Total non-current liabilities$66B$202B$8.81T$12.4T$126.2B
Capital lease obligations$0.00$448B$60B$126B$186.5B
Total liabilities$85.9T$107.1T$58.7T$48.4T$11.4T
Common stock$14.3T$13.4T$10.2T$10.1T$128.5B
Retained earnings-$-762.39T-$-558.57T-$-316.97T-$-140.04T-$-39.44T
Accumulated other comprehensive income (loss)$4.79T$4.47T$4.42T$4.42T$672.1B
Total equity$683.4T$757.5T$288.4T$430.1T$56.6T
Total investments$146.2T$62.4T$0.00$0.00$138T
Total debt$202B$448B$60B$126B$186.5B
Net debt-$-489.8T-$-771.3T-$-340.39T-$-467.6T-$-60.19T
Cash flow statement
FYFYFYFYFY
Net income-$-203.82T-$-241.6T-$-176.94T-$-22.63T-$-41.79T
Depreciation and amortization$220B$113B$49B$9B$5B
Stock-based compensation$59.4T$33.6T$24.6T$4.12T$1.24T
Change in working capital-$-7.94T-$-32.67T$5.87T$10.4T$4.47T
Accounts receivable-$-13.28T$0.00$4.03T-$-4.18T$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$4.91T-$-12.95T$5.07T$4.81T$6.56T
Net cash provided by operating activities-$-147.78T-$-158.56T-$-141.22T$10.7T-$-29.51T
Investments in property, plant and equipment-$-246B-$-672B-$-24B-$-221B-$-24B
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-174.92T-$-62.85T-$-24B-$-221B-$-24B
Common stock issued$29.5T$645.5T$8.91T$397T$84.7T
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$29.5T$659.5T$8.91T$391.9T$84.7T
Net change in cash-$-280.42T$431.3T-$-127.28T$407.6T$50.5T
Cash at end of period$491.3T$771.7T$340.5T$467.7T$60.1T
Operating cash flow-$-147.78T-$-158.56T-$-141.22T$10.7T-$-29.51T
Capital expenditure-$-246B-$-672B-$-24B-$-221B-$-24B
Free cash flow-$-148.03T-$-159.24T-$-141.24T$10.4T-$-29.54T
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About NewAmsterdam Pharma Company N.V.

        NewAmsterdam Pharma Company N.V. is a biopharmaceutical firm currently in the clinical development phase, committed to enhancing therapeutic options for individuals living with metabolic diseases. The company's primary experimental treatment, obicetrapib, is an innovative, selective agent designed to inhibit Cholesteryl Ester Transfer Protein (CETP). Clinical trials have shown this compound to be effective in both lowering "bad" low-density lipoprotein cholesterol (LDL-C) and significantly elevating "good" high-density lipoprotein cholesterol (HDL-C) simultaneously. Founded in 2019, this Dutch company maintains its headquarters in Naarden.

        CEO
        Michael Harvey Davidson Facp.
        Employees
        100
        Beta
        0.11

        Explore

        Frequently asked questions

        What is the intrinsic value of NewAmsterdam Pharma Company N.V. (NAMSW)?

        NewAmsterdam Pharma Company N.V. (NAMSW) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is NAMSW undervalued?

        NAMSW trades at a price of $18.45 (Sep 19, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Sep 19, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.